$67 in France and $798 in US–Why Prescription Drug Prices Are so High in US

Prescription drugs cost more in the United States than anywhere else in the world. President Donald Trump and some bipartisan senators want to change that.

In all, the president has taken at least a dozen actions to reduce prescription drug costs, while no less than nine Senate bills aim for the same results.

Some of these ideas have been introduced before.

There have been modest successes, including a pilot program begun by Trump in 2020 to cap insulin costs for Medicare Part B beneficiaries at $35 per month. At the time, a single vial of insulin cost about $100 in the United States.

That program was a success, and the idea was later broadened to include all Medicare beneficiaries through the Inflation Reduction Act of 2022. By 2024, most major drug companies had voluntarily limited out-of-pocket expenses for insulin for all U.S. customers to $35.

Yet Americans still pay nearly three times as much for prescription medication as any peer nation, often even more.

Trulicity, a medication for Type 2 diabetics, was listed for $67 in France, according to a 2021 Government Accountability Report. In the United States, it cost $798.

Meanwhile, Remlivid, an oral cancer medication, was listed for $4,723 in Australia. In the United States, it was listed at almost five times that price: $22,048.

Why? One answer is that other governments leverage the power of their national health plans to control pricing, while the United States lacks a comprehensive national prescription drug strategy.

The solution, according to at least one senator, is to stop putting patches on a broken system and take a comprehensive approach to regulating the entire pharmaceutical supply chain.

How Others Do It

Some nations can negotiate low prices for prescription drugs because they have national health care plans, which gives them near complete control over the drug market. Here’s how that works for some, according to the Government Accountability Office.

Australia

Australia has a national health care system that is partly administered by state, territorial, and local governments.

Prescription drug pricing is set at the national level, starting with an assessment of the drug’s value. That assessment is made by Australia’s independent Pharmaceutical Benefits Advisory Committee, which evaluates new drugs for cost-effectiveness and may recommend them for inclusion on the list of approved medications under the national health plan.

That decision is made by Australia’s national minister of health, who then negotiates with the manufacturer to determine a price. Among other considerations, the health minister evaluates the impact of adding the drug on the country’s budget.

Canada

Canada keeps prescription prices low in two ways. First, Canada’s federal government sets a maximum allowable price for each medication. The government bases this price, in part, on the therapeutic value of the drug. That value may be higher if the drug is the first of its kind, or lower if there are similar drugs already on the market.

Second, the country’s 13 provincial and territorial health plans negotiate pricing jointly with manufacturers, combining the power of their respective markets.

France

France has a national health care system that includes prescription drugs.

The French government negotiates prices with manufacturers based on an assessment of the therapeutic value of the drug. The country also places a cap on total prescription spending.

The Drawbacks

These arrangements significantly lower prescription costs for the government and for patients. But there are drawbacks.

When a U.S. insurance company can’t negotiate an acceptable price from a drug manufacturer, the insurer may choose not to cover the drug. However, another company will often cover it, so patients still have options.

However, when a drug is omitted from a national health plan, it may be more difficult to find it or afford it anywhere in that country.

For example, Signifor, a drug used to treat hormonal diseases, was not available in Ontario, Canada, according to a 2021 study by the Government Accountability Office. Some forms of diabetes drug Trulicity were not available in Australia. Cancer medicine Revlimid 5 milligram and 10 milligram capsules were not available in France.

Or, drugs left off the national coverage list may still be available, but at a higher price.

Drug shortages are another problem.

In countries with national health plans, pharmaceutical companies have less incentive to ensure supply. Companies  will favor markets where there is more potential for profit.

“[Drug] shortages are a natural outcome of imposing prices divorced from free market processes,” Jeremy Nighohossian, a senior fellow at the Competitive Enterprise Institute, a libertarian think tank, told The Epoch Times.

“It would mean less treatments and cures and would jeopardize the hundreds of billions our member companies are planning to invest in America—threatening jobs, hurting our economy and making us more reliant on China for innovative medicines.”

The US System

In the United States, various government agencies, private health plans, and commercial insurance companies each take their own approach to controlling prescription costs.

Premium Picks

The Inflation Reduction Act of 2022 authorized Medicare to negotiate prices with insurance companies.

However, all these medications are of a lesser-expensive type known as small-molecule drugs, according to C. Michael White of the University of Connecticut School of Pharmacy. None of the more costly large-molecule drugs used to treat cancer and other diseases were discounted.

White thinks greater savings are possible. “Private insurers negotiate the price of all drugs with manufacturers, so why is the federal government only negotiating a handful each year?” he told The Epoch Times.

Insurers generally outsource prescription drug negotiations to pharmacy benefit managers. These companies both negotiate prices and process pharmacy claims for insurers.

In theory, this should result in lower prices for consumers and greater efficiency for insurers, but that’s not always the case, according to Sen. Chuck Grassley (R-Iowa).

Pharmacy benefit managers “exercise growing influence on prescription drug supply chain,” Grassley told a Senate Judiciary Committee hearing on pharmaceutical competition May 13.

“As the middleman, they determine what medications a patient can use and how much the patient pays at the pharmacy counter.”

While pharmacy benefit managers claim to lower costs, Grassley pointed to what he called “opaque” business practices, saying the profits made by pharmacy benefit managers have increased “in ways that don’t add up based on the services they provide.”

This scattershot approach won’t work, according to Sen. Thom Tillis (R-N.C.), who believes Congress must step back and evaluate the entire medication supply chain to decide “how we ultimately address this problem.”

“All these other things are short-sighted, unsustainable measures that are not going to produce the result,” Tillis said on May 13.

Under Trump’s Most Favored Nation Prescription Drug policy, the first round of target prices is set to be delivered by Health and Human Services to pharmaceutical makers by June 11, aiming to align American drug prices with those of comparably developed nations.

Original News Source Link – Epoch Times

Running For Office? Conservative Campaign Consulting – Election Day Strategies!